Solid tumour comprehensive molecular profiling

In a prospective clinical sequencing programme covering more than 10,000 patients with advanced cancer, at least one actionable alteration was identified in 36.7% of patients. The information that targeted gene panels generate can inform diagnostic classification, guide therapeutic decisions and provide prognostic insights, and the clinical significance of a variant is established for therapy, diagnosis and prognosis. The analysis is therefore diagnostically, prognostically and therapeutically relevant. For a given tumour entity, the WHO Classification of Tumours sets out the diagnostic criteria and, where they are established, the diagnostic molecular features. The analyses that are relevant for that entity are set out by the National Comprehensive Cancer Network and by the European Society for Medical Oncology. The 638 genes cover the recurrently altered oncogenes and tumour suppressor genes across the common solid tumour entities, so the tumour can be characterised without committing to an entity-specific test first. It is performed on tumour material and is ordered where the molecular profile of the tumour is to be established broadly, rather than by an analysis directed at a single tumour entity.

Treatment options and algorithms are set out for each tumour entity by the and by the .

• WHO Classification of Tumours Editorial Board. WHO Classification of Tumours series. Lyon: International Agency for Research on Cancer. Available from: , accessed 8 August 2026.
• Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23(6):703-713. PMID: 28481359. PMCID: PMC5461196. Erratum: Nat Med. 2017;23(8):1004. PMID: .
• Jennings LJ, Arcila ME, Corless C, Kamel-Reid S, Lubin IM, Pfeifer J, et al. Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2017;19(3):341-365. PMID: . PMCID: PMC6941185.
• Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4-23. PMID: . PMCID: PMC5707196.
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Treatment by Cancer Type. Available from:  , accessed 8 August 2026.
• European Society for Medical Oncology. ESMO Clinical Practice Guidelines. Available from: , accessed 8 August 2026.The recommendations on the use of next-generation sequencing in advanced cancer are published as: Mosele MF, Westphalen CB, Stenzinger A, Barlesi F, Bayle A, Bièche I, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2024;35(7):588-606. PMID: . Corrigendum: Ann Oncol. 2025;36(4):472. PMID: .